Integrating electronic health records and GWAS summary stats to predict progression of autoimmune diseases from preclinical stages, 2025, Chen Wang

Discussion in 'Other health news and research' started by Mij, Jan 3, 2025.

  1. Mij

    Mij Senior Member (Voting Rights)

    Messages:
    10,078
    Abstract
    Autoimmune diseases often exhibit a preclinical stage before diagnosis. Electronic health record (EHR) based-biobanks contain genetic data and diagnostic information, which can identify preclinical individuals at risk for progression. Biobanks typically have small numbers of cases, which are not sufficient to construct accurate polygenic risk scores (PRS). Importantly, progression and case-control phenotypes may have shared genetic basis, which we can exploit to improve prediction accuracy.

    We propose a novel method Genetic Progression Score (GPS) that integrates biobank and case-control study to predict the disease progression risk. Via penalized regression, GPS incorporates PRS weights for case-control studies as prior and forces model parameters to be similar to the prior if the prior improves prediction accuracy.

    In simulations, GPS consistently yields better prediction accuracy than alternative strategies relying on biobank or case-control samples only and those combining biobank and case-control samples. The improvement is particularly evident when biobank sample is smaller or the genetic correlation is lower. We derive PRS for the progression from preclinical rheumatoid arthritis and systemic lupus erythematosus in the BioVU biobank and validate them in All of Us. For both diseases, GPS achieves the highest prediction, and the resulting PRS yields the strongest correlation with progression prevalence.
    LINK
     
    Sean and Yann04 like this.
  2. Utsikt

    Utsikt Senior Member (Voting Rights)

    Messages:
    1,219
    Location:
    Norway
    I can’t comment on their methods or the validity of their statements, but could this be usefull for finding a biomarker for ME/CFS?

    Does anyone know how this compares to the methods of DecodeME and BioQuest?
     
  3. Jonathan Edwards

    Jonathan Edwards Senior Member (Voting Rights)

    Messages:
    16,367
    Location:
    London, UK
    My reading is that this is about predicting early disease once you have a biomarker. Just how useful it is to try to be precise about predicting clinical disease from preclinical states is a bit unclear to me. You might end up everyone having yearly checks to see how many diseases they might get next year. Most people would probably find that petty dispiriting.
     
    alktipping, Trish and RedFox like this.

Share This Page